Page 44 - Read Online

Goncalves et al. Neuroimmunol Neuroinflammation 2019;6:6 I http://dx.doi.org/10.20517/2347-8659.2019.08 Page 3 of 3

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive
polyneuropathy. Ann Clin Transl Neurol 2015;2:960-71.
2. Stathopoulos P, Alexopoulos H, Dalakas MC. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev
Neurol 2015;11:143-56.
3. Querol L, Siles AM, Alba-Rovira R, Jauregui A, Devaux J, et al. Antibodies against peripheral nerve antigens in chronic inflammatory
demyelinating polyradiculoneuropathy. Sci Rep 2017;7:14411.
4. Kira JI, Yamasaki R, Ogata H. Anti-neurofascin autoantibody and demyelination. Neurochem Int 2018; doi: 10.1016/
j.neuint.2018.12.011.
5. Schafer DP, Bansal R, Hedstrom KL, Pfeiffer SE, Rasband MN. Does paranode formation and maintenance require partitioning of
neurofascin 155 into lipid rafts? J Neurosci 2004;24:3176-85.
6. Illa I. Arthur asbury lecture: chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of
auto-immunity to nodal components. J Peripher Nerv Syst 2017;22:418-24.
7. Kriebel M, Wuchter J, Trinks S, Volkmer H. Neurofascin: a switch between neuronal plasticity and stability. Int J Biochem Cell Biol
2012;44:694-7.
8. Hortsch M, Nagaraj K, Mualla R. The L1 family of cell adhesion molecules: a sickening number of mutations and protein functions.
Adv Neurobiol 2014;8:195-229.
9. Pomicter AD, Shroff SM, Fuss B, Sato-Bigbee C, Brophy PJ, et al. Novel forms of neurofascin 155 in the central nervous system:
alterations in paranodal disruption models and multiple sclerosis. Brain 2010;133:389-405.
10. Ogata H, Matsuse D, Yamasaki R, Kawamura N, Matsushita T, et al. A nationwide survey of combined central and peripheral
demyelination in Japan. J Neurol Neurosurg Psychiatry 2016;87:29-36.
11. Bailly L, Mongin M, Delorme C, Apartis E, Saheb S, et al. Tremor associated with chronic inflammatory demyelinating polyneuropathy
and anti-neurofascin-155 antibodies. Tremor Other Hyperkinet Mov (N Y) 2018;8:606.
12. Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.
Neurology 2016;86:800-7.
13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the
McDonald criteria. Ann Neurol 2011;69:292-302.
14. Kawamura N, Yamasaki R, Yonekawa T, Matsushita T, Kusunoki S, et al. Anti-neurofascin antibody in patients with combined central
and peripheral demyelination. Neurology 2013;81:714-22.
15. Klehmet J, Staudt M, Diederich JM, Siebert E, Meinl E, et al. Neurofascin (NF)155- and NF186-specific T cell response in a patient
developing a central pontocerebellar demyelination after 10 years of CIDP. Front Neurol 2017;8:724.
16. Shimizu M, Koda T, Nakatsuji Y, Ogata H, Kira JI, et al. A case of anti-neurofascin 155 antibody-positive combined central and
peripheral demyelination successfully treated with plasma exchange. Rinsho Shinkeigaku 2017;57:41-4.
17. Itaya K, Inoue M, Iizuka N, Shimizu Y, Yuki N, et al. A case of a 17-year-old male with neurofascin-155 antibody-positive chronic
inflammatory demyelinating polyradiculoneuropathy presenting with tremor and ataxia. Rinsho Shinkeigaku 2016;56:633-6.
18. Stich O, Perera S, Berger B, Jarius S, Wildemann B, et al. Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis. J
Neurol Sci 2016;364:29-32.